Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 11/20 | 0.47 |
| ▸ | CCNA2 | P20248 | 10/20 | 0.47 |
| ▸ | CDK2 | P24941 | 10/20 | 0.47 |
| ▸ | CCNA1 | P78396 | 10/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | IGF1R | P08069 | 2/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4285751 | 0.91 | AURKA (0.47) | AURKACCNA2CDK2CCNA1TDP1 | |
| SCHEMBL1373684 | 0.84 | IGF1R (0.40) | AURKACCNA2CDK2CCNA1TDP1 | |
| SCHEMBL2678720 | 0.82 | MET (0.50) | AURKACCNA2CDK2CCNA1TDP1 | |
| SCHEMBL1373681 | 0.82 | IGF1R (0.55) | AURKACCNA2CDK2CCNA1IGF1R | |
| SCHEMBL2678341 | 0.82 | IGF1R (0.63) | AURKACCNA2CDK2CCNA1IGF1R | |
| SCHEMBL2924317 | 0.80 | AURKA (0.52) | AURKACCNA2CDK2CCNA1IGF1R | |
| SCHEMBL2919887 | 0.80 | AURKA (0.63) | AURKACCNA2CDK2CCNA1IGF1R | |
| SCHEMBL2925541 | 0.79 | CCNA2 (0.48) | AURKACCNA2CDK2CCNA1IGF1R | |
| SCHEMBL2915889 | 0.79 | CCNA2 (0.52) | AURKACCNA2CDK2CCNA1IGF1R | |
| SCHEMBL4287742 | 0.79 | HTR6 (0.39) | PARP1PARP2ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461193-B2 | Substituted pyrrolo-pyrazole derivatives active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-06-11 | — | — | US | disclosed |
| US-20090163503-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2009-06-25 | — | — | US | disclosed |
| EP-1963326-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.r.l. (IT) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007068637-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163503-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K5, MAP3K19, MAP3K3 | AURKA 383/4885CCNA2 1504/4885CDK2 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.